A5022547198- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Cardiovascular Disease and Adiposity
Suburban Hospital
2025
National Institute of Neurological Disorders and Stroke
2025
Johns Hopkins University
2024
Sidney Kimmel Comprehensive Cancer Center
2024
Patients with acute ischemic stroke (AIS) treated endovascular therapy (EVT) may develop hyperemia due to loss of relative cerebral blood flow (rCBF) autoregulation. Hyperemia can be detected on two types MRI perfusion weighted imaging: dynamic susceptibility contrast (DSC) and arterial spin labeling (ASL). The aim this study was compare ASL-rCBF DSC-rCBF post-EVT explore the association between final infarct volume (FIV). This is a retrospective analysis GUARDS cohort in ongoing prospective...
446 Background: Numerous combos of ICIs and Tyrosine Kinase Inhibitors (TKIs) have received approval for the management mccRCC. Specific peripheral blood cell counts reflect inflammation impact anti-tumor immunity, here we investigated their role as biomarkers clinical benefit to ICI in RCC. Methods: We performed a retrospective study 179 mccRCC patients treated with ≥ 4 weeks (2013-2023), where examined baseline 6-week post-treatment Neutrophil Lymphocyte ratio (NLR), Red Distribution Width...
4547 Background: ICI combinations (combos) in the form of dual or plus tyrosine kinase inhibitors (TKI) combos currently represent most effective therapies mRCC patients (pts). However, there is an unmet need to discover biomarkers predictive clinical benefit combos. Circulating cytokines are important regulators immune system and may contribute cancer immunotherapy outcomes. In mRCC, prior studies showed that baseline expression influences outcomes monotherapy, but this association unknown...